BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32434852)

  • 1. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.
    Benitez JC; Remon J; Besse B
    Clin Cancer Res; 2020 Oct; 26(19):5068-5077. PubMed ID: 32434852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
    Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
    Herrscher H; Robert C
    Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?
    Alkassis M; Sarkis J; Tayeh GA; Kourie HR; Nemer E
    Immunotherapy; 2021 Apr; 13(6):459-463. PubMed ID: 33557589
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
    Sarver M; Brown MC; Rhodin KE; Salama AKS; Beasley GM
    Hum Vaccin Immunother; 2022 May; 18(3):1943987. PubMed ID: 34254900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
    Wang J; Cao L; Xu S
    Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
    O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
    Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
    Miyashita M; Ishida T
    Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
    Ren S; Xiong X; You H; Shen J; Zhou P
    Front Immunol; 2021; 12():689132. PubMed ID: 34149730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
    Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.